Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-01-2013 | Original Paper

Individual risk assessment in bladder cancer patients based on a multi-marker panel

Authors: Tilman Todenhöfer, Jörg Hennenlotter, Stefan Aufderklamm, Ursula Kühs, Georgios Gakis, Miriam Germann, Arnulf Stenzl, Christian Schwentner

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2013

Abstract

Purpose

To investigate whether a combined application of urine cytology (CYT) and molecular markers for bladder cancer (BC) can predict tumor aggressiveness.

Methods

The study comprised 2,113 patients who underwent urethrocystoscopy and transurethral resection of the bladder. CYT, fluorescence in situ hybridization (FISH), immunocytology (uCyt+) and nuclear matrix protein 22 test (NMP22-ELISA) were performed. Results of the individual tests and of a multi-marker panel were correlated with pT-stages and tumor grades.

Results

Five hundred and two of 2,113 (23.8 %) patients had BC. False-negative test rates of CYT (p < 0.001), FISH (p = 0.01) and NMP22-ELISA (p = 0.05) were lower in patients with muscle-invasive BC compared with patients with non-muscle-invasive BC. Furthermore, false-negative rates of CYT (p < 0.001), FISH (p = 0.0002) and NMP22-ELISA (p < 0.001) were lower in patients with G3/CIS compared with patients with G1–G2 BC. In patients with evidence of tumor in urethrocystoscopy, the presence of simultaneously positive CYT and NMP22 was associated with a 20-fold risk for G3/CIS (p < 0.0001).

Conclusions

This is the first study investigating the combined use of four urine markers in addition to cystoscopy to predict tumor aggressiveness. Our results indicate that combined application of urine markers as an adjunct to cystoscopy may facilitate identification of patients harboring high-grade tumors.

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. doi:10.1016/j.eururo.2011.03.017

Bubendorf L (2011) Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma—FISHing for the right catch. Acta Cytol 55(2):113–119. doi:10.1159/000323652 CrossRefPubMed

Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P (2001) Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 116(1):79–86. doi:10.1309/K5P2-4Y8B-7L5A-FAA9 CrossRefPubMed

Budman LI, Kassouf W, Steinberg JR (2008) Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2(3):212–221PubMed

Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ (2007) A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 178(1):68–73 (discussion 73). doi:10.1016/j.juro.2007.03.028

Greene KL, Berry A, Konety BR (2006) Diagnostic utility of the ImmunoCyt/uCyt+ test in bladder cancer. Rev Urol 8(4):190–197PubMed

Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y (2006) Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295(3):299–305. doi:10.1001/jama.295.3.299 CrossRefPubMed

Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178(6):2314–2330. doi:10.1016/j.juro.2007.09.003 CrossRefPubMed

Hennenlotter J, Huber S, Todenhofer T, Kuehs U, Schilling D, Aufderklamm S, Gakis G, Schwentner C, Stenzl A (2011) Point-of-care tests for bladder cancer: the influencing role of hematuria. Adv Urol 2011:937561. doi:10.1155/2011/937561 PubMed

Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhausser H, Bierfreund HG, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Bruning T, Stenzl A (2012) Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int. doi:10.1111/j.1464-410X.2011.10883.x

Karakiewicz PI, Benayoun S, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Marberger MJ, Shariat SF (2006) Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 97(5):997–1001. doi:10.1111/j.1464-410X.2006.06036.x CrossRefPubMed

Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, Jocham D, Ziegler A, Vonthein R (2010) Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 57(4):595–606. doi:10.1016/j.eururo.2009.11.041 CrossRefPubMed

Kehinde EO, Al-Mulla F, Kapila K, Anim JT (2011) Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer. Scand J Urol Nephrol 45(2):113–121. doi:10.3109/00365599.2010.533694 CrossRefPubMed

Kipp BR, Tyner HL, Campion MB, Voss JS, Karnes RJ, Sebo TJ, Halling KC, Zhang J (2008) Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer. Am J Clin Pathol 130(4):552–559. doi:10.1309/DFJUHY3WPC9GUU2W CrossRefPubMed

Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M (1999) Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 161(5):1486–1489CrossRefPubMed

Papanicolaou GN, Marshall VF (1945) Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 101(2629):519–520. doi:10.1126/science.101.2629.519 CrossRefPubMed

Riesz P, Lotz G, Paska C, Szendroi A, Majoros A, Nemeth Z, Torzsok P, Szarvas T, Kovalszky I, Schaff Z, Romics I, Kiss A (2007) Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res 13(3):187–194CrossRefPubMed

Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, Jansz K, Bridge JA, Johansson SL, Persons DL, Gibson JS (2006) Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176(1):44–47. doi:10.1016/S0022-5347(06)00576-3 CrossRefPubMed

Shariat SF, Casella R, Wians FH, Jr., Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI (2004) Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 45(3):304–313 (author reply 313). doi:10.1016/j.eururo.2003.10.020

Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Ludecke G, Boman H, Sawczuk I, Friedrich MG, Casella R, Mian C, Eissa S, Akaza H, Serretta V, Huland H, Hedelin H, Raina R, Miyanaga N, Sagalowsky AI, Roehrborn CG, Karakiewicz PI (2006) Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 176(3):919–926 (discussion 926). doi:10.1016/j.juro.2006.04.017

Shariat SF, Karam JA, Lotan Y, Karakiewizc PI (2008) Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10(2):120–135PubMed

Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 162(1):53–57CrossRefPubMed

Stenzl A, Penkoff H, Dajc-Sommerer E, Zumbraegel A, Hoeltl L, Scholz M, Riedl C, Bugelnig J, Hobisch A, Burger M, Mikuz G, Pichlmeier U (2010) Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : a multicenter randomized, double-blind, placebo-controlled trial. Cancer. doi:10.1002/cncr.25523

Todenhofer T, Hennenlotter J, Tews V, Gakis G, Aufderklamm S, Kuehs U, Stenzl A, Schwentner C (2011) Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. Urol Oncol. doi:10.1016/j.urolonc.2011.10.011

Todenhofer T, Hennenlotter J, Kuhs U, Tews V, Gakis G, Aufderklamm S, Stenzl A, Schwentner C (2012a) Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology 79(3):620–625. doi:10.1016/j.urology.2011.10.067 CrossRefPubMed

Todenhöfer T, Hennenlotter J, Witstruk M, Gakis G, Aufderklamm S, Kuehs U, Stenzl A, Schwentner C (2012b) Influence of renal excretory function on the performance of urine based markers to detect bladder cancer. J Urol. doi:10.1016/j.juro.2011.09.023

Tritschler S, Scharf S, Karl A, Tilki D, Knuechel R, Hartmann A, Stief CG, Zaak D (2007) Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 51(2):403–407 (discussion 407–408). doi:10.1016/j.eururo.2006.08.001

Yoder BJ, Skacel M, Hedgepeth R, Babineau D, Ulchaker JC, Liou LS, Brainard JA, Biscotti CV, Jones JS, Tubbs RR (2007) Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 127(2):295–301. doi:10.1309/ADJL7E810U1H42BJ CrossRefPubMed

Title: Individual risk assessment in bladder cancer patients based on a multi-marker panel
Authors: Tilman Todenhöfer
Jörg Hennenlotter
Stefan Aufderklamm
Ursula Kühs
Georgios Gakis
Miriam Germann
Arnulf Stenzl
Christian Schwentner
Publication date: 01-01-2013
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1297-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

MALDI-imaging segmentation is a powerful tool for spatial functional proteomic analysis of human larynx carcinoma

The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review

Clinico-epigenetic combination including quantitative methylation value of DKK3 augments survival prediction of the patient with cervical cancer

Tripeptidyl peptidase II in human oral squamous cell carcinoma

Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis

The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials